- Brachman PS, Gold H, Plotkin S, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52: 632-45.
- Centers for Disease Control. Observational study of anthrax vaccine, 1960s. Report obtained by FOIA to CDC, August 2000.
- Bioport. Anthrax vaccine adsorbed. Package insert March 1999. Online: http://www.bioportcorp.com/ Anthraxins.htm (accessed June 1999).
- Pittman M. HEW memorandum to reference file no. 67-70, 2 November 1970.
- Plotkin SA, Brachman PS, Utell M, Bumford FH, Atchison MM. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med 1960; 992-1001.
- Brachman PS, Plotkin SA, Bumford FH, Atchison MM. An epidemic of inhalation anthrax, the first in the twentieth century. . Epidemiology. Am J Hyg 1960; 72: 6-23.
- Sharma S. Verbal testimony: DOD's mandatory anthrax vaccine immunization program for military personnel. Hearing before the House Subcommittee on National Security, Veterans' Affairs and International Relations. 29 April 1999. Serial no. 106-26. Washington: US Government Printing Office, 1999.
- Food and Drug Administration. Biological products: bacterial vaccines and toxoids: implementation of efficacy review. Proposed rule. Federal Register 1985; 50(240): 51002-17.
- Michigan Biologic Products Institute. Investigational New Drug Application BB-IND 3723, 20 September 1996.
- Nass M. Anthrax vaccine: model of a response to the biological warfare threat. Infect Dis Clin North Am 1999; 13: 187-208. Online: http://www.anthraxvaccine.org/AVmodel.htm
- Pomerantsev AP, Staritsin NA, Mockov YUV, Marinin LI. Expression of cereolysin AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic infection. Vaccine 1997; 15: 1846.
- Michigan Biologic Products Institute Confidential Analytical Laboratory Anthrax Potency Review. AVA lots manufactured 1990-1997. Prepared by R Merriman, 8 December 1997, p. 1.
- Food and Drug Administration Memorandum from Jeanne Novak to Carolyn Hardegree, 10 December 1997. Online: http://www.anthraxvaccine.org/suppdocs/doc5.htm
- Department of Defense document DASG-HCD-D: medical biological warfare defense plan (undated, unclassified), signed by Brigadier General Bruce T Miketinac. Online: http://www.anthraxvaccine.org/ suppdocs/doc 12/htm
- Ivins BE, Fellows PF, Nelson GO. Efficacy of a standard human anthrax vaccine against Bacillus anthraxcis spore challenge in guinea pigs. Vaccine 1994; 12: 872.
- Institute of Medicine. Chemical and Biological Terrorism: Research and Development to Improve Civilian Medical Response. Washington: National Academy Press, 1999, pp. 134-6.
- Chan K-C. Medical readiness: safety and efficacy of the anthrax vaccine. GAO Report T-NSIAD-99-148. 29 April 1999.
- Zoon K. The Defense Department's Universal Anthrax Vaccine Program. Testimony before the Senate Armed Services Committee, 12 July 2000. Federal News Service 2000.
- Research Working Group of the Persian Gulf Veterans' Coordinating Board. Annual Report to Congress: Federally sponsored research on Gulf War veterans' illnesses for 1998. Department of Veterans' Affairs, June 1999.
- National Institutes of Health Technology Assessment Workshop Panel. The Persian Gulf experience and health. JAMA 1994; 272: 391-6.
- Institute of Medicine. Health Consequences of Service During the Persian Gulf War: Recommendations for Research and Information Systems. Washington: National Academy Press, 1996.
- Persian Gulf Veterans' Coordinating Board. A working plan for research on Persian Gulf veterans' illnesses, November 1996. Online: http://www.gulflink.osd.mil/varpt/framing.html
- Presidential Advisory Committee on Gulf War Veterans' Illnesses. Interim Report. Washington DC: US Government Printing Office, 15 February 1996. Online: http://www.gwvi.ncr.gov/interim.html
- Presidential Advisory Committee on Gulf War Veterans' IIlnesses. Final Report. Washington DC: US Government Printing Office, 31 December 1996. Online: http://www.gwvi.ncr.gov/toc-f.html
- Presidential Advisory Committee on Gulf War Veterans' Illnesses. Special Report. Washington DC: US Government Printing Office, October 1997. Online: http://www.gwvi.ncr.gov/tocl.html
- Pittman PR, Sjogren MH, Hack D, Franz D, Makuch RS, Arthur JS. Serologic Response to Anthrax and Botulinum Vaccines (Protocol NO, FY 92-95, M109, Log No.A-5747) Final Report to the US FDA. Fort Detrick, MD: US Army Medical Research Institute of Infectious Diseases.
- Institute of Medicine. Gulf War and Health, Vol. 1 : Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines. Washington: National Academy Press, 2000.
- Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999; 282: 2104-6.
- Unwin C, Blatchley N, Coker W et al. Health of UK servicemen who served in the Persian Gulf War. Lancet 1999; 353: 169-78.
- Straus SE. Commentary. Lancet 1999; 353: 162-3.
- Hotoph M, David A, Hull L, Ismail K, Unwin C, Wessely S. Role of vaccinations as risk factors for ill health in veterans of the Gulf War: cross sectional study. Br Med J 2000; 320: 1363-7.
- Hotoph M. Reanalysis of Gulf War vaccination data does not contradict findings. Br Med J 2000; 321 : 761-2.
- Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans. Am J Epidemiol 2000; 152: 991-1001.
- Office of the Special Assistant to the Secretary of Defense for Gulf War Illnesses. Military Medical Recordkeeping During and After the Gulf War: Interim Report. Washington, DC: US Department of Defense, 1999. Online: http://www.gulflink.osd.mil/nirk/
- Office of the Special Assistant to the Secretary of Defense for Gulf War Illnesses. Information Paper: Vaccine Use During the Gulf War. Washington, DC: US Department of Defense, 2000. Online: http://www.gulflink.osd.mil/va/
- Cherry N. Health and exposures of United Kingdom Gulf War veterans. Part II: The relation of health to exposure. Occup Environ Med 2001 ; 58: 299-306.
- Mahan CM, Kang HK, Ishii EK et al Anthrax Vaccination and Self-reported Symptoms, Functional Status and Medical Conditions in the National Health Survey of Gulf War Era Veterans and their Families. Washington, DC: Environmental Epidemiology Service, Veterans' Health Administration.
- Secretary of the Navy. DON Anthrax Vaccination Implementation Program (AVIP). 29 April 1998. SECNAVINST 6230.4.
- Piel M. Verbal testimony to House Subcommittee on National Security, Veterans' Affairs and International Relations, 21 July 1999. Online: www.house.gov/reform/ns/hearings/testimony/piel.htm
- Surgeon General NOTAM Risk Management Lessons. SG NOTAM 99-005. 30 July 1999.
- Mootrey GT. The Vaccine Adverse Event Reporting System and anthrax vaccine. Presented to the Institute of Medicine Committee on Anthrax Vaccine Safety and Efficacy, 3 October 2000.
- Fukuda K, Nisenbaum R, Stewart G et al Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA 1998; 280: 981-8.
- Nass M. Testimony: DOD's mandatory anthrax vaccine immunization program for military personnel. Hearing before the House Subcommittee on National Security, Veterans' Affairs and International Relations. 29 April 1999. Serial no. 106-26. US Government Printing Office, 1999. Online: http:// www.house.gov/reform/ns/hearings/testimony/nass2.htm
- Chan K-C. Medical readiness: issues concerning the anthrax vaccine. 21 July 1999. GAO Report GAO/T-NSIAD-99-226.
- Tanner J. Dover study of adverse reactions following anthrax vaccine. Unpublished. Online: http:// www.anthraxvaccine.org
- Institute of Medicine Committee on Health Effects Associated with Exposures During the Gulf War. An Assessment of the Safety of the Anthrax Vaccine: a Letter Report. 30 March 2000. Washington: National Academy Press. Online: http://www.nap.edu/catalog/9811 .html
- Nicolson GL, Nass M, Nicolson NL. The anthrax vaccine controversy. Questions about its efficacy, safety and strategy. Med Sentinel 2000; 5: 97-101.
- US House of Representatives, Committee on Government Reform. Unproven Force Protection. US Government Printing Office. 17 February 2000. Online: http://www.house.gov/reform/ns/reports/ anthraxl.pdf
- Food and Drug Administration. CBER Annual Report, FY 1999. Online: http://www.fda.gov/cber/ inside/annrpt.htm#bioterr
- Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 1999; 17: 340-4.
- Zoon KC. Vaccines, pharmaceutical products, and bioterrorism : challenges for the U.S. Food and Drug Administration. Emerg Infect Dis 1999; 5: 534-6.
Journal of Nutritional & Environmental Medicine
Volume 12, 2002 - Issue 4